13,778 Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Danske Bank A S

Danske Bank A S increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 171,842 shares of the pharmaceutical company’s stock after acquiring an additional 13,778 shares during the quarter. Danske Bank A S’s holdings in Vertex Pharmaceuticals were worth $89,841,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $11,975,849,000. State Street Corp lifted its holdings in shares of Vertex Pharmaceuticals by 1.2% during the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after acquiring an additional 141,320 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Vertex Pharmaceuticals by 1.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock worth $1,613,209,000 after acquiring an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Vertex Pharmaceuticals by 1.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock worth $1,533,248,000 after acquiring an additional 29,287 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $1,509,651,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on VRTX. Morgan Stanley decreased their price objective on shares of Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 3rd. Barclays raised their target price on Vertex Pharmaceuticals from $617.00 to $626.00 and gave the company an “overweight” rating in a report on Wednesday, November 4th. Cantor Fitzgerald lifted their price target on Vertex Pharmaceuticals from $595.00 to $619.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. Rothschild & Co Redburn boosted their price target on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Truist Financial upped their price objective on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $596.44.

Vertex Pharmaceuticals Price Performance

VRTX stock traded down $4.02 during trading on Friday, reaching $538.60. 755,937 shares of the company were exchanged, compared to its average volume of 1,580,871. The company has a market capitalization of $136.56 billion, a price-to-earnings ratio of 34.66, a P/E/G ratio of 2.87 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.89. The company has a 50-day moving average of $522.37 and a two-hundred day moving average of $483.84. Vertex Pharmaceuticals Incorporated has a twelve month low of $412.27 and a twelve month high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the prior year, the business earned $4.80 EPS. The business’s quarterly revenue was up 11.8% on a year-over-year basis. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.